Abstract
Paxlovid is a promising, orally bioavailable novel drug for SARS--CoV--2 with excellent safety profiles. Our main goal here is to explore the pharmacometric features of this new antiviral. To provide a detailed assessment of Paxlovid, we propose a hybrid multiscale mathematical approach. We demonstrate that the results of the present \textit{in silico} evaluation match the clinical expectations remarkably well: on the one hand, our computations successfully replicate the outcome of an actual \textit{in vitro} experiment; on the other hand we verify both the sufficiency and the necessity of Paxlovid's two main components (nirmatrelvir and ritonavir) for a simplified \textit{in vivo} case. Moreover, in the simulated context of our computational framework we visualize the importance of early interventions, and identify the time window where a unit--length delay causes the highest level of tissue damage. Finally, the results' sensitivity to the diffusion coefficient of the virus is explored in details.
Connections
Explore this paper’s authors, topics and related work.
Building this map preview
BZPEER is loading the nearby papers, people, topics and institutions for this page.
Reviews 0
Write a review
No reviews yet.
Discussion 0
Add a comment
No comments yet.